• Nxera Pharma licensed exclusive rights to Idorsia's Fabry disease candidate lucerastat in Japan and selected Asia-Pacific markets, excluding China.
• The agreement includes South Korea and Taiwan, with an upfront payment of CHF 7 million to Idorsia.
• Idorsia is eligible for royalties on net sales in the licensed markets.
• Nxera will contribute to the global Phase 3 program, taking responsibility for clinical development in Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.